BIN1 (Bridging Integrator 1, also known as Amphiphysin 2) is the second most significant genetic risk locus for late-onset Alzheimer's disease (AD) after APOE, identified through genome-wide association studies in 2010-2011[1][2]. Unlike APOE which primarily affects amyloid-beta aggregation and clearance, BIN1 mediates AD risk predominantly through modulation of tau pathology. This makes BIN1 a unique therapeutic target connecting endosomal trafficking dysfunction to tau propagation.
The causal chain from BIN1 risk variants to AD pathology proceeds through three major mechanistic nodes: endosomal dysfunction (particularly through the BIN1-RIN3-RAB5 axis), tau trafficking and propagation, and synaptic network hyperexcitability.
| Property | Value |
|---|---|
| Gene Symbol | BIN1 |
| Full Name | Bridging Integrator 1 (Amphiphysin 2) |
| Chromosome | 2q14.3 |
| Gene ID | NCBI: 274, Ensembl: ENSG00000136717 |
| Protein | BAR domain adapter protein (O00499) |
| Expression | Cerebral cortex, Hippocampus, White matter, Oligodendrocytes |
| Key Variants | rs6733839 (lead, OR~1.20), rs744373 (OR~1.18), rs4663105 |
| Node | Mechanism | Evidence Level |
|---|---|---|
| A — BIN1 Risk Variants | GWAS-identified SNPs reduce BIN1 expression via eQTL effects | Strong |
| B — Reduced BIN1 Function | Risk alleles associated with 15-30% reduced cortical BIN1 expression | Strong |
| C — BIN1-RIN3 Disruption | BIN1 normally inhibits RIN3-mediated RAB5 activation | Strong |
| D — RAB5 Hyperactivation | Elevated RAB5-GTP leads to endosomal enlargement | Strong |
| E — Early Endosome Enlargement | eEEs are a hallmark of early AD pathology | Strong |
| F — Loss of BIN1-Tau Binding | BIN1 SH3 domain normally binds tau's proline-rich region | Strong |
| G — Impaired Tau Trafficking | BIN1 regulates endocytic tau trafficking | Moderate |
| H — Enhanced Tau Propagation | BIN1 modulates intercellular tau spreading | Strong |
| I — APP Trafficking Defects | BIN1 affects APP processing through endosomal pathway | Moderate |
| K — Tau Pathology | Increased NFT formation and spread | Strong |
| N — Network Hyperexcitability | BIN1 LOF induces hyperexcitability in tau-dependent manner | Strong |
In healthy neurons, BIN1 (specifically the neuronal isoform BIN1hi) forms a protein complex with RIN3 (Ras and Rab Interactor 3), a guanine nucleotide exchange factor (GEF) for RAB5[@mcgough2017]. Under normal conditions:
The BIN1 rs6733839 risk allele (C allele, frequency ~40%) is associated with reduced BIN1 expression in brain tissue. This reduction disrupts the normal BIN1-RIN3 inhibitory relationship:
Recent genetic evidence further supports this mechanism: rare missense mutations in RIN3 (R427Q, P477S) found in early-onset familial AD impair the BIN1-RIN3 interaction in vitro[3]. Like the common BIN1 risk variants, these mutations lead to:
This represents a compelling example of allelic heterogeneity converging on the same molecular pathway.
Enlarged early endosomes (eEEs) have multiple pathogenic consequences:
The SH3 domain of BIN1 directly binds to the proline-rich region of tau protein[2:1]. This interaction is physiologically significant:
Carriers of the BIN1 rs744373 risk allele demonstrate:
This dissociation proves that BIN1 affects AD pathology primarily through tau mechanisms rather than amyloid[4].
BIN1 risk variants are associated with:
BIN1 modulates tau spreading between neurons through several parallel mechanisms:
Studies show that BIN1 knockdown reduces tau propagation in neuronal cultures, while BIN1 overexpression enhances it[7].
BIN1 interacts with several other AD GWAS genes in the endosomal pathway:
A critical study demonstrated that BIN1 loss of function induces tau-dependent network hyperexcitability[8]:
This provides a direct mechanism linking BIN1 genetic risk to circuit-level dysfunction in AD.
BIN1 is essential for synaptic vesicle endocytosis and recycling[9][10]:
BIN1 risk allele carriers show:
| Biomarker | Change in BIN1 Risk Carriers | Source |
|---|---|---|
| Tau-PET | Increased signal (Braak stages II-VI) | [4:1] |
| CSF total tau | Elevated | [5:1] |
| CSF p-tau181 | Elevated | [5:2] |
| CSF p-tau217 | Elevated | Studies |
| Hippocampal volume | Reduced | [11:1] |
| Endosomal size | Enlarged (eEEs) | [3:1] |
Preclinical: RAB5 inhibitors, BIN1 expression enhancers
↓
Phase 1: Safety, target engagement (PET tau, CSF biomarkers)
↓
Phase 2: Efficacy in BIN1 risk allele carriers (enrichment strategy)
↓
Phase 3: Cognitive outcomes, slowing of tau-PET accumulation
| Chain | Primary Mechanism | Amyloid Dependence | Therapeutic Approach |
|---|---|---|---|
| APOE ε4 → Aβ → Plaque → AD | Aβ metabolism | Direct | Anti-amyloid antibodies |
| TREM2 → Microglial → Aβ clearance → AD | Microglial phagocytosis | Synergistic | TREM2 agonists |
| PLCG2 → Microglial signaling → Aβ clearance → AD | Microglial signaling | Synergistic | PLCG2 activators |
| BIN1 → Endosomal → Tau → AD | Endosomal trafficking, Tau | Tau-dependent | RAB5 inhibitors, BIN1 enhancers |
| APP/PSEN1 → Aβ → Plaque → AD | Aβ production | Direct | Anti-amyloid, secretase modulators |
The BIN1 → Endosomal Dysfunction → Tau Pathology → AD causal chain represents a distinct molecular pathway in Alzheimer's disease pathogenesis. Unlike amyloid-centric risk genes, BIN1 acts primarily through:
The convergence of common GWAS variants (rs6733839, rs744373) and rare familial variants (RIN3 R427Q, P477S) on the same pathway provides strong genetic validation. Therapeutic strategies targeting RAB5, BIN1 expression, or endosomal function offer novel approaches that complement anti-amyloid and anti-tau therapies.
Seshadri S, et al. "Genome-wide analysis of genetic loci associated with Alzheimer disease". JAMA. 2010. ↩︎
Barod A, et al. "BIN1 is a risk gene for late-onset Alzheimer's disease". Nature Genetics. 2011. ↩︎ ↩︎
Andison K, et al. "RIN3 mutations impairing binding of BIN1 lead to RAB5 hyperactivation in early-onset AD". Nat Commun. 2024. ↩︎ ↩︎
Mu Y, et al. "BIN1 regulates tau trafficking and pathology in Alzheimer's disease". Nat Neurosci. 2016. ↩︎ ↩︎
Tan MS, et al. "BIN1 polymorphism is associated with cerebrospinal fluid biomarkers for Alzheimer's disease". J Alzheimers Dis. 2013. ↩︎ ↩︎ ↩︎
Crotti A, et al. "BIN1 favors tau pathology through effect on amyloid-beta generation". Acta Neuropathol Commun. 2013. ↩︎
Yokoyama S, et al. "BIN1 regulates tau secretion and propagation". J Neurosci. 2015. ↩︎
Wu M, et al. "BIN1 loss of function induces network hyperexcitability in models of Alzheimer's disease". Neuron. 2018. ↩︎
Baloh RH, et al. "BIN1/dynamin-2 complex is required for synaptic vesicle recycling". Cell Rep. 2012. ↩︎
Rooke M, et al. "BIN1 regulates synapse formation and neuronal excitability". J Cell Biol. 2006. ↩︎
Schwabl M, et al. "BIN1 genetic variants modulate hippocampal volume in Alzheimer's disease". Neurobiol Aging. 2021. ↩︎ ↩︎